We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 3.03 | 2.39% | 130.03 | 132.80 | 128.76 | 130.08 | 6,247,264 | 17:41:22 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Merck & Co. on Thursday said its cancer drug Keytruda met one of two primary endpoints in a Phase 3 study in a form of colorectal cancer.
The Kenilworth, N.J., drug maker said Keytruda significantly improved progression-free survival as first-line treatment in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer compared with chemotherapy.
Merck said the study will continue without changes to evaluate overall survival, the other dual primary endpoint, adding that Keytruda's safety profile was consistent with previous studies, with no new safety signals identified.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2020 07:27 ET (11:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
